Q-omics provides the consensus-scored RARRES2 profile across patient tissues and cancer cell-line models. RARRES2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RARRES2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RARRES2 protein abundance shows 31,115 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, KIRC, and PDAC as cancer lineages where RARRES2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RARRES2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RARRES2 survival associations across molecular data types. RARRES2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RARRES2 RNA expression–survival associations across cancer types. High RARRES2 expression shows unfavorable associations in KIRC, UVM, OV and LGG, but favorable associations in MESO and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RARRES2 RNA expression.
This table summarizes RARRES2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RARRES2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RARRES2 shows lower tumor expression in LUAD, UCEC, LUSC, BLCA and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher RARRES2 RNA expression in tumor versus normal tissue (log2 FC = +1.943, t-test p < 0.001).
This table shows molecular features associated with RARRES2 in patient tissues and cancer cell lines. In patient samples, RARRES2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RARRES2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
